Application of pyridinopyrazine derivative in preparation of medicament for treating leukemia
By using the pyridopyrazine derivative GK921 as a drug component, the proliferation of leukemia cells was inhibited, and the problem of poor inhibition of leukemia cells in the prior art was solved, effective inhibition of a variety of leukemia cells was achieved, and high safety was achieved.
CN119700771APending Publication Date: 2025-03-28SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)
2 Cites 0 Cited by
Patent Information
- Application Number
- CN202510004301.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-01-02
- Publication Date
- 2025-03-28
AI Technical Summary
Technical Problem
The prior art is difficult to effectively inhibit the proliferation of leukemia cells, especially the inhibitory effect on acute myeloid leukemia and chronic myeloid leukemia cells is not good.
Method used
A pyridinopyrazine derivative, called GK921, is used as a pharmaceutical ingredient to form a pharmaceutical preparation for the treatment of leukemia by inhibiting the proliferation of leukemia cells.
Benefits of technology
GK921 has a significant proliferation inhibitory effect on acute myeloid leukemia, chronic myeloid leukemia and other leukemia cells, and is basically non-toxic to normal non-tumor cells and is highly safe.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention discloses application of a pyridopyrazine derivative or a salt thereof in preparation of a medicament for treating leukemia. The pyridopyrazine derivative as shown in the formula (I) or the salt of the pyridopyrazine derivative is used for preparing a medicine for treating leukemia. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art